Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Akcea Therapeutics announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation to volanesorsen (ISIS-APOCIIIRx) for the treatment of patients with Familial Chylomicronemia Syndrome (FCS).
Patients with FCS treated with volanesorsen achieved substantial reductions in apoC-III, triglycerides, chylomicrons and apoC-III-associated very low density lipoprotein-cholesterol (VLDL-C) particles as observed in a Phase 2 study. Akcea is conducting an international multi-center, randomized, double-blind, placebo-controlled Phase 3 study in patients with FCS.
RELATED: Approval for Novel Cholesterol Drug Recommended By FDA Panel
Volanesorsen is an antisense drug designed to target apoC-III. It is currently in development to treat patients with severely high triglycerides either as a single agent or in combination with other triglyceride-lowering agents.
For more information visit AkceaTx.com.
